Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment

Area of Science:

• Rheumatology
• Immunology
• Pediatrics

Background:

• Juvenile dermatomyositis (JDM) is a rare, severe autoimmune condition impacting children's muscles and skin.
• Recent progress in JDM research has been driven by collaborative networks, enhancing understanding of its pathogenesis.
• Identifying immunogenetic risk factors and aetio-pathogenesis pathways is crucial for JDM management.

Purpose of the Study:

• To summarize recent advancements in the recognition, assessment, and treatment of JDM.
• To highlight the role of research networks in defining JDM's immunogenetic landscape.
• To discuss the utility of autoantibodies and validated tools in sub-phenotyping and standardizing outcomes.

Main Methods:

• Review of findings from large collaborative research networks in JDM.
• Analysis of identified immunogenetic risk factors and aetio-pathogenesis pathways.
• Evaluation of myositis-associated and myositis-specific autoantibodies for JDM sub-phenotyping.
• Assessment of partially validated tools for disease activity and damage standardization.

Main Results:

• Definition of key immunogenetic risk factors and potential aetio-pathogenesis pathways in JDM.
• Utilization of autoantibodies to sub-phenotype JDM based on clinical features, outcomes, and genetics.
• Implementation of standardized tools for assessing JDM disease activity and damage.
• Emergence of aggressive and novel therapeutic strategies for JDM.

Conclusions:

• Collaborative research networks have significantly advanced JDM understanding and management.
• Autoantibodies and standardized tools are vital for precise JDM sub-phenotyping and outcome measurement.
• New treatment approaches, including biologics, offer improved outcomes and reduced corticosteroid toxicity in JDM.